RT Journal Article
SR Electronic
T1 Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.21.20210203
DO 10.1101/2020.10.21.20210203
A1 Salama, Carlos
A1 Han, Jian
A1 Yau, Linda
A1 Reiss, William G.
A1 Kramer, Benjamin
A1 Neidhart, Jeffrey D.
A1 Criner, Gerard J.
A1 Kaplan-Lewis, Emma
A1 Baden, Rachel
A1 Pandit, Lavannya
A1 Cameron, Miriam L.
A1 Garcia-Diaz, Julia
A1 Chávez, Victoria
A1 Mekebeb-Reuter, Martha
A1 Menezes, Ferdinando Lima
A1 Shah, Reena
A1 González-Lara, Maria F.
A1 Assman, Beverly
A1 Freedman, Jamie
A1 Mohan, Shalini V.
YR 2020
UL http://medrxiv.org/content/early/2020/10/23/2020.10.21.20210203.abstract
AB Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Safety and efficacy of the anti–interleukin-6 receptor antibody tocilizumab was evaluated in patients hospitalized with Covid-19 pneumonia.Methods Nonventilated patients hospitalized with Covid-19 pneumonia were randomized (2:1) to tocilizumab (8 mg/kg intravenous) or placebo plus standard care. Sites enrolling high-risk and minority populations were emphasized. The primary endpoint was cumulative proportion of patients requiring mechanical ventilation or who had died by Day 28.Results Of 389 randomized patients, 249 patients received tocilizumab and 128 received placebo in the modified intent-to-treat population (Hispanic/Latino, 56.0%; Black/African American, 14.9%; American Indian/Alaska Native, 12.7%; White, 12.7%; other/unknown, 3.7%). The cumulative proportion (95% confidence interval [CI]) of patients requiring mechanical ventilation or who had died by Day 28 was 12.0% (8.52% to 16.86%) and 19.3 % (13.34% to 27.36%) for the tocilizumab and placebo arms, respectively (log-rank P=0.0360; hazard ratio, 0.56 [95% CI, 0.33 to 0.97]). Median time to clinical failure up to Day 28 favored tocilizumab over placebo (hazard ratio 0.55 [95% CI, 0.33 to 0.93]). All-cause mortality by Day 28 was 10.4% with tocilizumab and 8.6% with placebo (weighted difference, 2.0% [95% CI, – 5.2% to 7.8%). In the safety population, serious adverse events occurred in 15.2% of tocilizumab patients (38/250 patients) and 19.7% of placebo patients (25/127).Conclusions This trial demonstrated the efficacy and safety of tocilizumab over placebo in reducing the likelihood of progression to requiring mechanical ventilation or death in nonventilated patients hospitalized with Covid-19 pneumonia.Trial registration ClinicalTrials.gov NCT04372186Competing Interest StatementC.S. reports personal fees from Genentech, Inc. J.H., L.Y., W.G.R., B.K., and S.V.M are employees and shareholders of Genentech, Inc. and have filed a patent for a method of treating pneumonia, including COVID-19 pneumonia, with an IL-6 antagonist. J.D.N., L.P., M.L.C., J.G.-D., V.C., M.M.-R., F.L.M., and R.S. have nothing to disclose. G.J.C. reports, outside the submitted work, grants and personal fees from Galaxo Smith Kline, Boehringer Ingelheim, Chiesi, Mereo, Astra Zeneca, Pulmonx, Pneumrx, Olympus, Broncus, Lungpacer, Nuvaira, ResMed, Respironics, and Patara; personal fees from Verona, BTG, EOLO, and NGM; grants from Alung, Fisher Paykel, and Galapgos. E.K.-L. reports honorarium from ViiV outside the submitted work and is a site PI for a Genentech, Inc. sponsored clinical trial. R.B. reports her institution received support from Genentech, Inc. to perform this study. M.F.G.-L. reports personal fees from Pfizer, Stendhal, and Grupo Biotoscana during the conduct of the study and personal fees from Pfizer and Stendhal outside the submitted work. B.A. and J.F. are employees and shareholders of Genentech, Inc.Clinical TrialNCT04372186Funding StatementThis study was funded by Genentech, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients or their legally authorized representative gave informed consent. This study was conducted in accordance with the International Council for Harmonization E6 guideline for good clinical practice and the Declaration of Helsinki or local regulations, whichever afforded greater patient protection. This study was approved by all study sites though the central institutional review boards Advarra Institutional Review Board or Western Institutional Review Board, and/or the following local ethics committees/institutional review boards: Aga Khan University Hospital Nairobi, COFEPRIS, Comité de Bioseguridad de Clínica Bajío CLINBA, S.C., Comité de Bioseguridad del Institut Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Comitě de ética em Pesquisa da Faculdade de Medicina do ABC, Comitě de ética em Pesquisa em Seres Humanos Pontifícia Univesidade Católica de Campinas - PUC CAMPI, Comite de Etica en Investigacion del Hospital General de Culiacan Dr Bernardo J Gastelum, Comité de ética Investigación Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Comite Nacional Transitorio de Etica de los Ensayos COVID-19, Ministerio de Salud Instituto Nacional de Salud, PPB ECCT, Sharp Healthcare Institutional Review Board, and St. Joseph Health Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). https://vivli.org/ https://vivli.org/members/ourmembers/ https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm